Molecular determinants of non-competitive antagonist binding to the mouse GPRC6A receptor


1. Introduction

Among G-protein coupled receptors (GPCRs), those of family 3 have recently been the focus of intense studies for the discovery of allosteric modulators binding to the transmembrane domains (TMs) [1]. This family includes 8 metabotropic receptors (mGluRs), 2 γ-aminobutyric acid type B receptors, 3 taste receptors, the calcium sensing receptor (CaSR), the GPRC6A for basic L-α-amino acids and seven orphan receptors [2]. These receptors display several key features including a long bilobed amino-terminal tail containing the orthosteric binding site and a cysteine-rich region connected to a hydrophobic domain formed by 7 putative transmembrane segments. Binding of the ligand to the orthosteric binding site is believed to induce structural changes within the seven TMs allowing signal transmission to the intracellular domain [3]. Preliminary studies indicated that the ligand binding pockets for positive and negative allosteric modulators are overlapping but not identical and identified subtle differences within the binding of the negative allosteric modulators [8–10].

Recently, it has been shown that NPS R-568, a selective and potent CaSR agonist, was also a positive allosteric modulator of the mGPRC6A [11]. These data suggested that other CaSR allosteric ligands might modulate mGPRC6A activation. The CaSR controls calcium homeostasis through the regulation of parathyroid hormone and calcitonin secretion but the functions of the receptor in tissues such as the kidney, the gastrointestinal tract,
bone cells and the brain where its expression has been reported are not well characterized [3–5,12]. The mGPRC6A receptor has been recently identified as a promiscuous L-α-amino acid sensor [13–15]. However, the functional roles of this receptor during embryonic development and in adult tissues are not well understood [16]. Generation of GPRC6A null mice has not allowed to delineate its physiological roles [17,18]. To further understand the evolutionary link between the CaSR and the mGPRC6A within family 3 of GPRCRs, we have evaluated the pharmacological properties, with respect to the mGPRC6A of three allosteric modulators of the CaSR with different chemical structures (Calindol, NPS 2143 and Calhex 231; Fig. 1A). We used site-directed mutagenesis of amino acid residues putatively delineating the allosteric binding pocket of the mGPRC6A to analyze the biochemical and pharmacological properties of this receptor.

2. Materials and methods

2.1. Compounds

Calindol[(R)-2-[(1-(1-naphthyl)ethylaminomethyl]-1H-indole, Calhex 231, (1S,25,1'R)-N1{(4-chlorobenzoxy)-N2-[(1-naphthyl)ethyl]2,1,3-diaminocyclohexene and NPS 2143, N-[(R)-2-hydroxypropyl]-1,1-dimethyl-2-(2-naphthyl)ethylamine, were from R.H. Dodd (Gif/Yvette, France), L-ornithine mono chloride (L-Orn) was from Sigma.

2.2. Plasmids

The wild-type (WT) mGPRC6A cDNA in pCR2.1 vector was from Prof. H. Bräuner-Osborne (Copenhagen, Denmark). To generate the Myc-mGPRC6A construct, a fragment encoding amino acid residues 21–928 was amplified by PCR. The restriction fragment Mlu–Sall was subcloned in pRK5-SP-myc vector [19], pcDNA3 plasmid containing the N-terminal myc-tagged human CaSR (hCaSR) was kindly provided by Prof. G.N. Hendy (Montreal, Canada) and was previously described [20]. GoG66D-containing plasmid was a kind gift of Dr. E. Kostenis (Bonn, Germany) and was described previously [21].

2.3. Site-directed mutagenesis

All point mutations in mGPRC6A and hCaSR were introduced using the QuikChange site-directed mutagenesis kit (Stratagene) with specific oligonucleotides (Eurobio, Les Ulis, France). All final constructions were verified by sequencing on both strands (Genome Express, Meylan, France). Oligonucleotide sequences are available upon request.

2.4. Cell culture and transfections

HEK293 cells (Eurobio, Les Ulis, France) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (Invitrogen) and were transiently transfected with plasmid containing WT or mutant hCaSR by electroporation as described [10]. In the case of WT or mutated mGPRC6A, 4 µg were supplemented with GoG66D (4 µg) and pRK5 empty vector (2 µg) [19]. After electroporation, cells were resuspended in culture medium and distributed on a 6-well plate for Western blot analysis or on a 24-well plate coated with poly-d-lysine (0.05 mg/ml, Sigma) for measurement of [3H]inositol phosphates ([3H]IP) formation. 48 h after transfection cells were used for analysis. Alternatively, the cells were resuspended in 13 ml of culture medium, then distributed (200 µl) on white 96-well plates (VWR) coated with poly-d-lysine (0.05 mg/ml) and used to measure inositol phosphate production using IP-One HTRF assay 48 h later.

2.5. [3H]IP formation

Cells were labeled with 0.5 µCi/well of myo-[3H]inositol (GE Healthcare) for 20 h in their growth medium. Measurement of [3H]IP accumulation for WT and mutant hCaSR was performed as described [10]. Their activities were determined in response to increasing extracellular Ca²⁺ or to NPS 2143 in the presence of 9 mM Ca²⁺. For measurement of WT and mutant mGPRC6A activities, cells were washed and preincubated 2 × 2 h at 37 °C in HBSS buffer (pH 7.4) containing 3.5 mM NaHCO₃, 20 mM HEPES, 1 mM CaCl₂ and 1 mg/ml bovine serum albumin. The activities of WT and mutant mGPRC6A were then determined in response to increasing concentration of L-Orn alone or in the presence of NPS 2143, Calhex 231 or Calindol (10 µM) and 2 mM Ca²⁺ as described [10,22]. Data are expressed as the average of duplicate determinations and are representative of 3–8 independent experiments. IC₅₀ for NPS 2143 on hCaSR and EC₅₀ for L-Orn were calculated using GraphPad Prism 2.01 (GraphPad Prism Software Inc., San Diego, CA). Significance was assayed by the Excel 98 Student’s t-test (Microsoft, Seattle, WA).
2.6. HTRF IP-One assay

HTRF experiments were performed following IP-One bulk kit (Cisbio, France) instructions with the following adaptations. 48 h after transfection HEK293 cells were washed and preincubated 2 x 2 h at 37 °C in 100 μl of HBSS buffer (as for measurement of [3H]IP formation). The buffer was then replaced with 70 μl of stimulation buffer containing the indicated L-Orn and drug concentrations and 2 mM Ca2+. After 30 min incubation at 37 °C, the reaction was stopped. Assay plates were then incubated for 1 h at room temperature. FRET and fluorescence signals were measured 50 μs after excitation at 337 nm, at 620 and 665 nm, using a Genios Pro apparatus (TECAN, Austria Gmbh). The assay signal was expressed as the HTRF ratio ([fluorescence at 665 nm]/fluorescence at 620 nm) × 104 and converted to nM of IP1 using an IP1 calibration curve.

2.7. Western blot analysis

Cell lysates and Western blots were performed as previously described [10]. Nitrocellulose membranes were probed for 2 h at room temperature with 9E10 (1:400), a mouse monoclonal anti-Myc antibody (Sigma). A horseradish peroxidase conjugated goat anti-mouse IgG was used as secondary antibody (Chemicon International). The immunoreactivity was revealed with enhanced chemiluminescence kit ECL (GE Healthcare).

2.8. Immunocytochemistry

The immunofluorescence experiments were performed essentially as described [23]. For Calindol pretreatment experiments, 24 h after transfection Calindol was added into the media to a final concentration of 20 μM. Equal amount of vehicle was added to control cells and incubation continued overnight. For the detection of the protein at the cell surface, cells were incubated for 90 min at 37 °C in the culture medium without serum with 9E10 (1:400) monoclonal antibody and then fixed in 4% paraformaldehyde. For the detection of the protein inside and at the cell surface, cells were first fixed in 4% paraformaldehyde, then permeabilized with 0.05% Triton X-100 and incubated for 2 h at RT in PBS–2% gelatin supplemented with 9E10 (1:400). A 1:100 dilution of FITC-labeled goat anti-mouse IgG (Sigma) was used as secondary antibody and Vectashield medium as mounting medium (AbCys, Paris, France). The immunofluorescence staining was visualized and analyzed under a Leica fluorescence microscope. Negative controls were performed in parallel on mock-transfected cells.

2.9. Residue numbering and nomenclature

The Ballesteros–Weinstein residue numbering scheme [24] was used throughout for GPCR TMs helices. For application to the secroud extracellular loop (ECL2), corresponding residues have been labeled 45x, 45 indicating the location between TMs 4 and 5 (therefore ECL2) and x a number relative to the conserved cysteine residue which is assigned number 50. Numbers lower than 50 thus describe upstream residues located between TM4 and C45.50. Numbers higher than 50 describe downstream residues located between C45.50 and TM5. For explicit numbering of residues in specific receptors, the UniProt [25] residue number is given before the Ballesteros number in superscript (e.g. E8167369 for mGPRC6A).

2.10. Three-dimensional model of the mouse GPRC6A and of the allosteric binding pocket

A model of the mGPRC6A TMs (residues 588–835) was derived from our previously published model of the hCaSR [10]. Both sequences (mGPRC6A: D588-K685; hCaSR: S607-K836) were aligned using standard settings of the ClustalW2 algorithm [26]. hCaSR residues were mutated to mGPRC6A residues using the Biopolymer module of the Sybyl 8.0 package (TRIPOS Assoc., Inc., St-Louis, USA) keeping dihedral angle values of the mutated side chains. Since no major insertion/deletion could be noticed, hydrogen atoms could be added using standard geometries in SYBYL. Starting coordinates were then embedded in a 10-Å wide water box (TIP3P model) in Amber 8.0 (University of California, San Francisco, CA 94158-2517, USA) and further refined with the ff03 force-field [27] by 2000 steps of steepest-descent followed by 3000 steps of conjugate-gradient energy-minimization.

2.11. Automated docking of NPS 2143 and Calindol

NPS 2143 and Calindol input three-dimensional structures were obtained by converting 2D Marvin sketches (ChemAxon Ltd., Budapest, Hungary) into three-dimensional mol2 files with Corina v3.4 (Molecular Networks, Erlangen, Germany). Both compounds were docked with Gold v4.0 docking program into a cavity delimited by 30 residues featuring a canonical ligand binding site of most if not all GPCRs [28] to which were added 5 amino acids encompassing the conserved cysteine residue in the second extracellular loop (L742–E746). Automated settings of the Gold genetic algorithm were chosen in order to scale parameters according to ligand flexibility. A maximum of 30 poses were saved for each ligand and the diversity of obtained binding modes was analyzed by computing molecular interaction fingerprints with the receptor model using the in-house developed IFP program [29].

3. Results

3.1. Calindol and NPS 2143 but not Calhex 231 are non-competitive antagonists of mGPRC6A

We have shown previously that Calhex 231 and NPS 2143 are negative allosteric modulators of the CaSR whereas Calindol and NPS R-568 act as positive allosteric modulators [9,10,30,31]. Recently, Pi et al. [11] have reported that NPS R-568 (0.5 μM) stimulated SRE promoter-luciferase reporter activity in HEK293 cells after transfection of a Mγc epitope tagged GPRC6A cDNA. This observation prompted us to analyze the effect of Calhex 231, NPS 2143 and Calindol at the mGPRC6A. First, we developed a functional assay for mGPRC6A based on a method previously published by Christiansen et al. [13]. We transiently co-transfected mGPRC6A and the promiscuous Goα(1660) protein in HEK293 cells and monitored IP formation upon stimulation with l-Orn. Increasing the concentration of l-Orn from 1 μM to 1 mM caused a 3–4-fold increase of IP accumulation measured using an HTRF (IP-One) or a radioactive ([3H]IP) assay, respectively (Suppl. Fig. 1). We did not detect an increase of IP accumulation in HEK293 cells transiently transfected solely with an empty plasmid, a plasmid containing the qG66D protein in HEK293 cells and monitored IP formation upon stimulation with l-Orn. Increasing the concentration of l-Orn from 1 μM to 1 mM caused a 3–4-fold increase of IP accumulation measured using an HTRF (IP-One) or a radioactive ([3H]IP) assay, respectively (Suppl. Fig. 1). We did not detect an increase of IP accumulation in HEK293 cells transiently transfected solely with an empty plasmid, a plasmid containing the mGPRC6A or the Goα(1660) after addition of 10 nM l-Orn (data not shown). Analysis of the l-Orn dose–response curves led to an EC50 for l-Orn of 44 ± 6 μM (mean ± S.E.M., n = 6) and 64 ± 5 μM (mean ± S.E.M., n = 9) using the HTRF or the radioactive assay, respectively (Tables 1 and 2). These data fit well with the affinity for l-Orn determined in an IP turnover assay at the mGPRC6A expressed in tsA201 cells [13].

Next, we evaluated the effects of Calhex 231, Calindol and NPS 2143 by analyzing the concentration–response curves for stimulation of IP formation in response to l-Orn in the absence or in the presence of 10 μM of these compounds. Incubation of HEK293 cells coexpressing mGPRC6A and Goα(1660) with Calindol or NPS 2143 caused a marked and significant reduction in the amplitude of the IP response as compared with the stimulation evoked with l-Orn.
alone whereas Calhex 231 did not (Fig. 1B and Table 2). Interestingly, despite the profound reduction of the response amplitude, the EC₅₀ values of L-Orn were not affected. These observations indicate that Calhex 231 is not an antagonist of mGPRC6A whereas both Calin dol and NPS 2143 are non-competitive antagonists of L-Orn binding to the mGPRC6A.

mGPRC6A and hCaSR display a high sequence homology not only throughout the extracellular domain but even more along the seven TMs. Based on a previously described model of hCaSR [10], we have now developed a model of mGPRC6A and used it to define a putative ligand binding site for allosteric modulators such as those identified for the CaSR and other family 3 GPCRs [10,28]. Thus, 33 mGPRC6A residues involved in this putative binding pocket were compared to those shown to delineate the hCaSR binding pocket (Fig. 2). 18 residues were identical and several others were conserved. Interestingly, 7 residues located in TM3, TM6 and TM7 previously demonstrated by site-directed mutagenesis to participate in calcilytic (NPS 2143 and Calhex 231) recognition by the hCaSR were identical. Among them, W6.48, F6.51, E7.39 and I7.43 have also been shown to participate in Calindol and NPS 2143 recognition. These signals were absent in mock-transfected cell preparations thereby indicating their specificity. A polypeptide complex migrating above 200 kDa was also observed and likely corresponds to intermolecular linked dimers of the receptor as previously observed (Fig. 3 B) [32]. The 115 kDa peptide might correspond to glycosylated receptors whereas the 105 kDa peptide is consistent with the molecular weight of the unglycosylated receptor. These signals were absent in mock-transfected cell preparations thereby indicating their specificity. A polypeptide complex migrating above 200 kDa was also observed and likely correspond to intermolecular linked dimers of the receptor as previously observed (Fig. 3 B) [32]. The 115 kDa peptide might correspond to glycosylated receptors whereas the 105 kDa peptide is consistent with the molecular weight of the unglycosylated receptor as previously reported for the rat and mouse GPRC6A [14,32] whereas the 80 kDa peptide presumably represents a proteolytic. Importantly, the expression pattern of the various mutant receptors was almost comparable to that of the WT receptor as previously reported for the rat and mouse GPRC6A.

### Table 2

<table>
<thead>
<tr>
<th>Receptor</th>
<th>L-Orn EC₅₀ (µM)</th>
<th>Maximal response (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>NPS 2143</td>
</tr>
<tr>
<td>WT</td>
<td>64 ± 5</td>
<td>62 ± 3</td>
</tr>
<tr>
<td>F800A</td>
<td>27 ± 3</td>
<td>30 ± 3</td>
</tr>
<tr>
<td>E816Q</td>
<td>89 ± 8</td>
<td>63 ± 3</td>
</tr>
</tbody>
</table>

Concentration–response curves for L-Orn alone (control) or in the presence of 10 µM NPS 2143, Calindol or Calhex 231 were generated as described in the legends of Figs. 1 and 5. Maximal response to 10 mM L-Orn alone (taken as 100%) or in the presence of NPS 2143, Calindol or Calhex 231 was compared for each receptor. Level of significance: *p < 0.001 compared with the control for each receptor.

### 3.2. Generation of point mutations and characterization of the mutant mGPRC6A receptors

We have mutated the 7 amino acids described above into alanine (see Fig. 2) by site-directed mutageneis to investigate their possible interaction with NPS 2143 and Calindol. These mutants and the WT mGPRC6A were transiently transfected into HEK293 cells. We then analyzed their ability to respond to L-Orn by measuring the accumulation of IPs, their expression by Western blotting and their subcellular distribution using a Myc antibody which recognizes the Myc epitope located at the amino-terminal tail of the WT and mutant receptors.

We first analyzed mGPRC6A immunoreactivity by microscopy using anti-Myc antibodies on permeabilized and non-permeabilized HEK293 transfected with the WT and the various mutant constructs. Myc immunoreactivity was detected at the cell surface of non-permeabilized HEK293 cells transfected with WT mGPRC6A (Fig. 3A). After cell permeabilization, immunoreactivity was also observed at the cytoplasmic level. In cells transfected with the empty vector, Myc immunoreactivity was not detectable under either condition (data not shown). These data suggest that mGPRC6A is addressed to the cell membrane. Under reducing SDS PAGE conditions, three polypeptides migrating with a mobility corresponding to molecular masses of 115, 105 and 80 kDa were identified in whole lysates from cells transfected with the WT receptor. These signals were absent in mock-transfected cell preparations thereby indicating their specificity. A polypeptide complex migrating above 200 kDa was also observed and likely correspond to intermolecular linked dimers of the receptor as previously observed (Fig. 3B) [32]. The 115 kDa peptide might correspond to glycosylated receptors whereas the 105 kDa peptide is consistent with the molecular weight of the unglycosylated receptor as previously reported for the rat and mouse GPRC6A [14,32] whereas the 80 kDa peptide presumably represents a proteolytic. Importantly, the expression pattern of the various mutant receptors was almost comparable to that of the WT receptor as accessed by immunoblotting (Fig. 3B) except for the...
Fig. 3. Functional analysis of the WT and mutant mGPRC6As.
(A) Analysis of mGPRC6A expression by immunocytofluorescence in HEK293 cells. Cells were transfected with the wild-type (WT) or mutant receptors. The extracellular N-terminal Myc tag was detected using an anti-Myc antibody on non-permeabilized (NP) or permeabilized (P) cells. Protein expression was visualized using a fluorescent secondary antibody detected by conventional microscopy. (B) Immunoblot analysis of whole cell lysates (4 μg proteins) from HEK293 cells transiently transfected with an empty vector (MOCK), or a vector containing the WT or the indicated mGPRC6A mutant, was performed following SDS polyacrylamide gel electrophoresis. mGPRC6A proteins were detected using the anti-Myc antibody 9E10. The position of the molecular mass markers is shown on the left (kDa). Arrow heads (black and white) on the right indicate major bands corresponding to the WT and mutant receptors and to a non-specific band, respectively. (C) Concentration–response curves of \( \text{L-Orn} \)-induced IP accumulation measured by the IP1 immunoassays in HEK293 cells transfected with WT or mutant receptors and coexpressing \( \text{G}_{q66D} \). The IP response to \( \text{L-Orn} \) is expressed as % of maximal response to 10 mM \( \text{L-Orn} \) observed at the WT receptor. Data are means of triplicates from a typical representative experiment out of 3–5.

signal corresponding to the 115 kDa peptide which was stronger in the F670A mutant. By contrast, in non-permeabilized cells, Myc immunoreactivity was detected at the cell membrane of F670A, W797A, F800A mutants and at a low level of F666A, but not R662A, E816A and I820A mutants. After cell permeabilization, immunoreactivity was detected at the cytoplasmic levels in HEK293 cells transfected with each mutant construct.

We then tested the functional activity of the WT and mutant receptors by analyzing their sensitivity to L-Orn. Among all tested mutants, only F800A displayed a dose–response curve to L-Orn comparable to the WT receptor (Fig. 3C and Table 1). All other tested mutants did not give a significant activity in response to L-Orn except the W797A mutant which showed a significant and reproducible increase in the IP response to elevated L-Orn concentration (up to 10 mM). Together with the expression and distribution profile of these proteins, these data suggest that the mGPRC6A proteins harboring the F666A, F670A, or W797A mutations are targeted to the cell membrane but have lost all or most of their sensitivity to L-Orn whereas the R662A, the E816A and I820A mutants are trapped inside the cell. In agreement, these last mutants, when transfected in HEK293 cells, did not lead to IP accumulation in response to L-Orn (10 mM) (Fig. 3 and Table 1). These data demonstrate that the mutation into alanine of 6 residues of the 7 putatively implicated in the recognition of NPS 2143 and Calindol, profoundly affects either the targeting of the protein or its sensitivity to L-Orn.

3.3. Calindol binding requires the E816 residue located in TM7 of mGPRC6A

We have previously shown that the residue E837 \( ^{7.39} \) plays a key role in both Calindol and NPS 2143 recognition in the hCaSR \[9\]. Here, the corresponding E816A \( ^{7.39} \) mGPRC6A mutant was trapped inside the cell which did not allow us to analyze its pharmacological properties. These data suggest that this mutation affects the three-dimensional structure of the receptor in such a way that it dramatically modifies its targeting to the cell membrane. We decided to mutate the E816A \( ^{7.39} \) residue into an aspartate, a glutamine or a leucine residue and to analyze the expression and the functional properties of the associated mutants in HEK293 cells. The aspartic acid and leucine substitution led to mutants that were also trapped inside the cell (Fig. 4A) whereas the glutamine mutant was well expressed at the cell membrane. Since the expression of these mutants was comparable to the expression of the WT receptor as judged by Western blot analysis of transfected cells, these data suggest that a slight variation in the length of the side chain (shorter in the case of aspartic acid and alanine) or its hindrance (in the case of leucine) disrupted the ternary structure of the mutant receptor affecting the targeting of the protein. However, a change of the acidic residue into the corresponding neutral amino acid did not lead to an apparent change in the distribution of the mutant receptor at the cell membrane. When these mutants were tested in
Functional effect of mutations affecting the E816 mGPRC6A residue.

HEK293 cells were transfected with the mock plasmid or with a plasmid encoding the WT, the E816Q, the E816D, or E816L mGPRC6A mutants. Analysis of mGPRC6A expression by immunocytofluorescence (non-permeabilized (NP) or permeabilized (P) cells) (A) and Western blot (B) were performed as described in the legend of Fig. 3A and B. The position of the molecular mass markers is shown on the left. Arrow heads on the right indicate the molecular weight of two major bands corresponding to mGPRC6A. (C) Concentration–response curves to l-Orn measured by the IP-One assay as described in Fig. 3C. Data are means of triplicates from a typical representative experiment out of 3–5.

We then tested the ability of NPS 2143 and Calindol to inhibit the IP response induced by l-Orn in HEK293 cells transfected with the F800A and E816Q mutants (Fig. 5A and B). Both Calindol and NPS 2143 (10 μM) reduced the IP response induced by l-Orn on the F800A mutant. Again, we observed a marked reduction of the maximal response without a modification of its EC50 suggesting that both compounds behaved as non-competitive antagonists. These data clearly indicate that the F800 residue does not interact with either antagonist. Interestingly, in HEK293 cells transfected with the E816Q mutant, the IP response to l-Orn was not modified by Calindol (10 μM) whereas the maximal response was diminished by NPS 2143 (10 μM) (Fig. 5B). These data suggest that the E816 residue is implicated in the recognition of Calindol but not of NPS 2143, which either indicates that recognition of NPS 2143 by mGPRC6A does not require the E816 residue or that the hydroxyl and amine function of NPS 2143 are still H-bonded to Q816.

Such interaction was not observed when E816L and E816A mutants were analyzed (Fig. 5C).

To compare the properties of the 7.39 residue from mGPRC6A and the hCaSR, we introduced the E837Q mutation into the hCaSR. This mutant responded well to Ca2+ (EC50 = 6.3 ± 0.1 mM) and with a maximal effect of Ca2+ comparable to that of WT hCaSR (Suppl. Fig. 2 and data not shown). We then established the dose–response curve of NPS 2143 required to block the Ca2+-induced IP response on this mutant. We observed that NPS 2143 inhibited Ca2+-induced IP response of the WT hCaSR with an IC50 = 0.4 ± 0.1 μM in agreement with our previous data [10] but had no effect on the E837Q mutant (Fig. 6). These data confirm that the E837 residue is implicated in NPS 2143 recognition in the hCaSR and that the 7.39 residue in the hCaSR and mGPRC6A are not strictly equivalent.

### 3.4. Hypothesized binding mode of Calindol and NPS 2143 to the mGPRC6A

A three-dimensional model of mGPRC6A was built from an earlier experimentally validated model of hCaSR [10]. There are only 4 out of the 33 cavity residues (2.57, 4.56, 45.19 and 45.51) which significantly differ between both receptors. Interestingly, two of them are located in the second extracellular loop and are known as ligand–anchoring residues for many GPCR ligands [33].

Automated docking of NPS 2143 and Calindol to the mGPRC6A model with Gold v4.0 program disclosed a preferred binding mode in which the secondary amine moiety of both compounds
Fig. 5. Effect of Calindol and NPS 2143 on the WT and mGPRC6A E816 and F800 mutants.

(A–B) The cells were transfected with the Gq(G66D) and the WT, F800A or E816Q mutant vector and the IP response to l-Orn was determined in buffer alone (□) or in the presence of 10 μM Calindol (♦) or NPS 2143 (▵). Data are expressed as % of WT receptor response (radioactive assay) to 10 mM l-Orn, which represented 4–8 times the IP basal level. Results are means of triplicates from a representative experiment out of 3–5 ones. (C) Cells were transfected with the WT, or indicated E816 mutant vector. 24 h after transfection, Calindol (20 μM) or control buffer were added to the culture medium and the cells were further incubated overnight. The receptor localization was analyzed by immunocytofluorescence as described in Fig. 3A.

Fig. 6. Effect of NPS 2143 on Ca2+-induced accumulation of IP by the WT and E837Q hCaSR transfected in HEK293 cells.
The cells were transiently transfected with the plasmid encoding the WT or E837Q hCaSR. The IP response induced by 9 mM Ca2+ was determined in the presence of increasing concentrations of NPS 2143 for the WT and mutant hCaSR. Data from one experiment out of two are expressed as % of maximal IP response (radioactive assay) observed with 9 mM Ca2+ which represented between 4 and 6 times the IP basal level.

is anchored through a salt bridge to the side chain of E8167.39 (Fig. 7). This main anchoring is further stabilized by an additional hydrogen bond to E816 from the indole nitrogen atom (Calindol) or the secondary alcohol group (NPS 2143). For both ligands, the bound conformation adopts a V-shape conformer in which the two terminal aromatic moieties are embedded in hydrophobic subpockets involving L5971.39, L6001.42, F6663.32, I8207.43, I8227.45 on the one side, and F6703.36, W7976.48, F8006.51 and the disulfide bridge C6593.25–C7444.50 on the other (Fig. 7).

4. Discussion

In this study, we have identified Calindol and NPS 2143 as the first two non-competitive antagonists of the mGPRC6A, a member of family 3 GPCRs. These two molecules have been shown to be allosteric modulators of the hCaSR and mediate non-competitive inhibition of l-Orn-induced mGPRC6A activation in cells transiently coexpressing mGPRC6A and Gq(G66D). Molecular modeling of the TMs region of the mGPRC6A identifies potential amino acid residues delineating a binding pocket for these two molecules. In addition, we have identified E8167.39 as a key residue involved in Calindol binding to the seven TMs. However, Calhex 231, another chemically different allosteric modulator of the hCaSR, was not active towards modulation of mGPRC6A activation. Altogether, these data demonstrate that the mGPRC6A and hCaSR receptor
Fig. 7. Proposed models of the mGPRC6A complexed with Calindol and NPS 2143.

Proposed interaction model between NPS 2143 (A), Calindol (B), and the mGPRC6A binding cavity. The seven TMs helices are indicated by yellow ribbons and only important ligand-contacting side chains are displayed as white balls and sticks. Residues are labeled according to the Ballesteros numbering scheme [24]. Three residues (45.50, 45.51, 45.52) of the second extracellular loop which cap the binding site of mGPRC6A allosteric modulators are also displayed. Carbon, oxygen, nitrogen and chlorine atoms are displayed in cyan (NPS 2143) or lavender (Calindol), red, blue and green, respectively.

The similarities between the mGPRC6A and the hCaSR are evident both through the large extracellular domain (ECD) and the 7 putative TMs that characterize family 3 of GPCRs [34]. However, a striking homology is also observed at the level of the allosteric ligand binding pocket of the mGPRC6A and the CaSR delineated by a set of amino acid residues located within or near the surface of the seven TMs. 18 out of the 33 amino acids lining the seven TMs binding pocket are strictly identical whereas comparison of those involved in the mGPRC6A and mGluR1–8 binding pockets indicates a much lower homology (data not shown). This suggests a putative cross pharmacology between mGPRC6A and hCaSR.

The first evidence of this came from the study of Pi et al. [11] which showed that the phenylalkylamine NPS R-568 stimulated SRE-luciferase and ERK activity in HEK293 cells transfected with a GPRC6A plasmid. We noticed that the E7.39 residue is present in both the mGPRC6A and CaSR but not in the 2 γ-aminobutyric acid type B receptors, mGlRs or taste receptors. This negatively charged residue participates in the recognition of Calindol, NPS 2143, Calhex 231 and NPS R-568 in CaSR [8–10,35,36] presumably via interaction with the protonated secondary amine present in these molecules. In order to investigate the properties of these molecules towards the mGPRC6A, we developed a Myc-tagged mGPRC6A expressing vector that we co-transfected with GqG66D. mGPRC6A was expressed at the cell membrane and we observed a robust activation of the PLC, as indicated by IP responses, upon stimulation with l-Orn and various amino acids including arginine and arginine derivatives (data not shown) suggesting that mGPRC6A directly interacts with this G-protein in agreement with a previous report [13]. Calindol, NPS 2143 and Calhex 231 on their own did not affect the IP response on mGPRC6A and did not potentiate the IP response induced by 1 μM l-Orn demonstrating that they do not behave as agonists or positive modulators of the mGPRC6A (data not shown). However,
a profound reduction in the amplitude of l-Orn-stimulated IP production was observed in the presence of Calindol and NPS 2143. Since the amplitude change was not accompanied by a modification in the EC50 of l-Orn, these data indicated that Calindol and NPS 2143 mediate non-competitive inhibition. These data are in agreement with the presence of the l-Orn binding site within the ECD as previously proposed for these receptors [7,15,37,38] and the location of an allosteric binding site for NPS 2143 and Calindol at the level of the TMs as proposed above.

We have generated a three-dimensional model of the seven TMs of the mGPRC6A that allowed us to identify the putative residues delineating the mGPRC6A allosteric binding pocket. To further test if these residues are implicated in the recognition of NPS 2143 and Calindol, we mutated seven of these residues into alanine and we also submitted the key E816Q - residue to discrete mutations (E816Q, E816D, and E816L). Whereas the mutant receptors were expressed at a level comparable to that of the WT receptor, the R662A, E816A, E816D, and I820A mutants did not reach the cell membrane or only at a low level, were trapped inside the cell and were unsurprisingly not responsive to l-Orn. The receptors harboring the F666A, the F670A and W797A mutations despite being expressed at the cell membrane, were characterized by a decrease of the IP response to l-Orn which was almost completely abrogated in F666A and F670A mutants. Both Calindol and NPS 2143 were able to mediate non-competitive inhibition of l-Orn-induced IP response on the F800A mutant expressed in HEK293 cells, suggesting that this residue does not substantially participate in the binding of these molecules. Interestingly, NPS 2143 but not Calindol was able to inhibit l-Orn-induced stimulation of the PLC in cells expressing the E816Q mutant. However, when the E816D mutant, which was trapped inside the cell, was expressed in HEK293 and preincubated with Calindol overnight, the receptor was then targeted to the cell membrane. This clearly indicated that this mutant receptor still recognizes Calindol. Thus, these data suggest that the protonated secondary amine of Calindol is anchored to the TM7 through an H-bond to the negatively charged E816 residue which is no longer possible in the E816Q mutant, but still possible in the E816D mutant. In the case of NPS 2143, the binding mode remains ambiguous since the hydroxyl moiety of NPS 2143 might still be H-bonded to Q816. Analysis of the CaSR harboring the same mutation at the identical position (E837Q) revealed that the hydroxyl and amine function of NPS 2143 cannot form an H-bond to the Q837 residue. These data demonstrate that despite sharing a similar ligand-binding pocket, important differences exist between these two preincubated with Calindol overnight, the receptor was then targeted to the cell membrane. This clearly indicated that this mutant receptor still recognizes Calindol. Thus, these data suggest that the protonated secondary amine of Calindol is anchored to the TM7 through an H-bond to the negatively charged E816 residue which is no longer possible in the E816Q mutant, but still possible in the E816D mutant. In the case of NPS 2143, the binding mode remains ambiguous since the hydroxyl moiety of NPS 2143 might still be H-bonded to Q816. Analysis of the CaSR harboring the same mutation at the identical position (E837Q) revealed that the hydroxyl and amine function of NPS 2143 cannot form an H-bond to the Q837 residue. These data demonstrate that despite sharing a similar ligand-binding pocket, important differences exist between these two receptors at the level of the allosteric binding site. A significant difference between hCaSR and mGPRC6A binding pockets resides in the nature of residue 45.51 following the conserved cysteine residue implicated in a disulfide bridge in the second extracellular loop. hCaSR presents a histidine at this position whose side chain contributes to one aromatic subpocket accommodating the naphthalene moiety of NPS 2143 [10]. In mGPRC6A, this residue is changed to glutamate (Fig. 2) whose acidic character completely modifies the overall properties of this subpocket and therefore promotes a V-shape bound conformation of the ligand (Fig. 7) and prevents contacts to other aromatic/hydrophobic residues in TMs 5 and 6 (e.g. Y804Q [35]). This particularly bent conformation of both ligands in the GPRC6A binding pocket may explain why the F800Q mutation to Ala does not affect their binding, by opposition to hCaSR where this residue is predicted to have much more surface contacts with extended conformations of bound ligands [9,10]. Interestingly, the neighboring residue Glu45.52 was also shown to mediate anchoring of F1105, a recently described allosteric regulator of CaSR [39].

It is also worthwhile noting that Calindol behaves as a positive allosteric modulator of the hCaSR and as a negative allosteric modulator of the mGPRC6 which also pinpoints a difference between the two receptors. Site-directed mutagenesis studies on the TMs allosteric site of metabotropic glutamate receptors have already indicated subtle but significant differences in the binding mode of positive and negative allosteric regulators [40] and it has also been demonstrated that closely related ligands can have varying efficacies spanning from negative to positive modulation [40,41].

Negative allosteric modulators of the CaSR have been identified [6,10], and are under intense investigation for the treatment of diseases linked to impaired Ca2+-homeostasis. Whereas the positive allosteric modulators presumably facilitate the signal transmitted to the seven TMs by the ECD after binding of the orthosteric ligand, it is thought that the negative allosteric modulators impede this signal. Analysis of the mechanisms of action of these allosteric modulators has revealed novel insights into the receptor activation process suggesting that conformational changes of the seven TMs is crucial for signal transmission [36]. Our data now suggest that mGPRC6A and hCaSR share similarities at the level of the allosteric binding sites for seven TMs modulators but also display important differences. We have published earlier that E837Q [37] is crucial for Calindol recognition in the CaSR. The present data clearly identify E816Q [39] to be important for negative allosteric modulation in the mGPRC6A. Therefore, it appears that this residue plays a central role in the activation process of the two receptors but is not able to discriminate by its own whether a molecule will be a positive or a negative modulator. Like other members of this class of GPCRs, activation of the mGPRC6A is believed to occur upon ligand binding to sites located within the extracellular domain constituted by its long amino-terminal tail [42,43] called a Venus flytrap module [44]. The subsequent conformational change which presumably occurs through the cysteine-rich region affects the seven TMs region leading to receptor activation. Interestingly, several mutations affecting residues located in TM3 and in TM6 of mGPRC6A affect the activation of the receptor by l-Orn. It is possible that these mutations maintain an inactive conformation of the seven TMs region. It is worth noting that the same mutations of these residues in the hCaSR have no or limited effect on Ca2+-mediated receptor activation [9,10] suggesting important differences in the activation process of these two receptors.

Our present data further highlight the complex processes linked to mGPRC6A and CaSR activation and again suggest important differences in these mechanisms. Therefore, further work is needed to understand how allosteric modulators such as NPS 2143 and Calindol can either block direct contact of the VFTM with the seven TMs region of the receptors which functions as a dimer, or can prevent the switch between the inactive and active conformation of the seven TMs region, thus preventing further rotation of TM6 required for activation of many GPCRs [45]. We can thus anticipate that our current model of the hCaSR and mGPRC6A, should facilitate the development of novel positive and negative allosteric modulators displaying improved affinity and selectivity and acting within the seven TMs region of these attractive drug targets. Together with the use of GPRC6A knockout mice [17,18], these molecules should help to further delineate the physiological roles of this receptor.

Acknowledgements

We thank Dr. E. Kostenis (Bonn, Germany) for GαqGEFlα and Dr. S. O’Regan for critical reading of the manuscript. This work was supported by an ANR (ANR-07-PHYSIOS-027-02) grant to M.R. and a grant from LEO Research Foundation (Copenhagen, Denmark).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.ceca.2009.09.004.
References


[23] V. Huang, Y. Zhou, W. Yang, et al., Identification and dissection of Ca(2+)-binding sites in the extracellular domain of human Ca(2+) receptor critical for response to Ca2+, and a positive allosteric modulator of the human Ca(2+) receptor, J. Biol. Chem. 282 (2007) 19000–19010.

